Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Theriva Biologics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −7 vs. Q3 2024
- Shares held
- 34.5K
- −457.7K (−93.0%) vs. Q3 2024
- Total value
- $60.3K
- −$618.3K (−91.1%) vs. Q3 2024
- New holders
- 2
- 2 more added
- Sold out
- 9
- 2 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 16,406 | $28.7K | 0.00% | −1,445−8.1% | Reduced |
| Citigroup Inc | 7,756 | $13.6K | 0.00% | +7,756 | New |
| BlackRock, Inc. | 7,568 | $13.2K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,391 | $2.44K | 0.00% | +730+110.4% | Added |
| Advisor Group Holdings, Inc. | 1,294 | $2.26K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 20 | $35 | 0.00% | +11+122.2% | Added |
| Iron Horse Wealth Management, LLC | 14 | $25 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 11 | $19 | 0.00% | −296−96.4% | Reduced |
| SBI Securities Co., Ltd. | 10 | $18 | 0.00% | +10 | New |
| Danske Bank A/S | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Heights Capital Management, Inc | 0 | $0 | 0.00% | −141,958−100.0% | Sold out |
| Anson Funds Management LP | 0 | $0 | 0.00% | −139,046−100.0% | Sold out |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| MSD Partners, L.P. | 0 | $0 | 0.00% | −27,316−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −20,200−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −13,566−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −11,806−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −10,120−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −495−100.0% | Sold out |
| Planning Capital Management Corp | – | – | – | – | Not filed |